Tiziana Life Sci PLC - Update on Timings and Corporate Actions
("Tiziana" or the "Company")
Update on Timings and Corporate Actions
ADR Ratio Change
JPMorgan has been closed for issuances and cancellations of the Company's American Depositary Shares ("ADS") since close of business
The former ratio of five (5) ordinary shares to one (1) ADS has been changed to two (2) ordinary shares per one (1) ADS and is effective on
There will be no change to the underlying ordinary shares.
Proposed StemPrintER Demerger
The Company continues to advance plans for the potential demerger of StemPrintER to a new company which will be called "AccuStem". The Company is currently seeking tax clearances for the proposed transaction and will then put the proposals to shareholders for approval. The record date for entitlement to participate in any distribution will be a date after the date on which the posting of the circular is announced (and not before). A further announcement will be made in due course.
The Company decision on cancellation of the trading of its shares on AIM has been postponed due to the continuing impact of COVID-19. No final decision on this matter will now be taken until at least Q4 2020.
The Company continues to pursue all of its clinical candidates in line with previous announcements. There are no new developments to report at the current time, either in relation to the COVID-19 focused projects, or the other ongoing studies.
As announced this morning, Dr
No new information will be given at this webinar (which is pre-recorded, save for the Q&A session) and which is intended merely to give attendees a summary overview of the Company's activities (condensing the more extensive information available on the Company's website).
For further enquiries:
| || |
+44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
+44 (0)20 7213 0880
| || |
+44 (0)20 3981 4173
This information is provided by RNS, the news service of the
Quick facts: Tiziana Life Sciences PLC
Market Cap: £269.54 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE